Metformin and lactic acidosis in an Australian community setting: the Fremantle Diabetes Study

Objective: To determine the incidence of lactic acidosis in community‐based patients with type 2 diabetes, with special reference to metformin therapy.

[1]  W. Winkelmayer,et al.  Cardiovascular risk and the thiazolidinediones: déjà vu all over again? , 2007, JAMA.

[2]  Felicia G Roberts,et al.  The Safety of Metformin in Heart Failure , 2007, The Annals of pharmacotherapy.

[3]  B. Zinman,et al.  Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy , 2006, Diabetes Care.

[4]  P. Montravers,et al.  Effect of metformin on survival rate in experimental sepsis. , 2006, Diabetes & metabolism.

[5]  T. Davis,et al.  Glycaemic levels triggering intensification of therapy in type 2 diabetes in the community: the Fremantle Diabetes Study , 2006, The Medical journal of Australia.

[6]  N. Clark,et al.  Standards of Medical Care in Diabetes: Response to Power , 2006 .

[7]  M. Stumvoll,et al.  Contraindications can damage your health—is metformin a case in point? , 2005, Diabetologia.

[8]  Ross T Tsuyuki,et al.  Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. , 2005, Diabetes care.

[9]  J. Prins,et al.  Metformin and serious adverse effects , 2004, The Medical journal of Australia.

[10]  J. Semmens,et al.  Long-Term Relative Survival in Elderly Patients After Carotid Endarterectomy: A Population-Based Study , 2003, Stroke.

[11]  M. Ravid,et al.  Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. , 2002, European journal of internal medicine.

[12]  D. Swanson,et al.  Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. , 2002, Archives of internal medicine.

[13]  A. Morris,et al.  Contraindications to metformin therapy in patients with Type 2 diabetes—a population‐based study of adherence to prescribing guidelines , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[14]  I. Mackay,et al.  Autoantibodies to glutamic acid decarboxylase in diabetic patients from a multi‐ethnic Australian community: the Fremantle Diabetes Study , 2000, Diabetic medicine : a journal of the British Diabetic Association.

[15]  Gerson Lesser.  Long-Term Prevention of Bone Loss , 2000, Annals of Internal Medicine.

[16]  K. Jamrozik,et al.  Mobile Australians: a moving target for epidemiologists , 2000, The Medical journal of Australia.

[17]  A. J. Bass,et al.  Population‐based linkage of health records in Western Australia: development of a health services research linked database , 1999, Australian and New Zealand journal of public health.

[18]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[19]  Jonathan B. Brown,et al.  Lactic Acidosis Rates in Type 2 Diabetes , 1998, Diabetes Care.

[20]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[21]  G. A. Fleming,et al.  Lactic acidosis in patients with diabetes treated with metformin. , 1998, The New England journal of medicine.

[22]  A. Garber,et al.  Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. , 1997, The American journal of medicine.

[23]  S. Curry,et al.  Treatment of lactic acidosis with dichloroacetate. , 1983, The New England journal of medicine.

[24]  D. Power.  Standards of medical care in diabetes. , 2006, Diabetes care.

[25]  E. Salpeter,et al.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. , 2003, The Cochrane database of systematic reviews.